Tumor Necrosis Factor Induces Tumor Promoting and Anti-Tumoral Effects on Pancreatic Cancer via TNFR1

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Chopra, Martin ^a   Lang, Isabell ^a   Salzmann, Steffen ^a   Pachel, Christina ^a,b   Kraus, Sabrina ^a   Bäuerlein, Carina A ^a   Brede, Christian ^a   Garrote, Ana Laura Jordán ^a   Mattenheimer, Katharina ^a   Ritz, Miriam ^a   Schwinn, Stefanie ^a   Graf, Carolin ^a   Schäfer, Viktoria ^a   Frantz, Stefan ^a,b   Einsele, Hermann ^a   Wajant, Harald ^a   Beilhack, Andreas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CD4+ FORKHEAD BOX P3+ REGULATORY T CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN; CELL STRAIN PANC02; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOTOPIC TRANSPLANTATION; PANCREAS ADENOCARCINOMA; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; TRANSCRIPTION REGULATION; TUMOR REJECTION; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; CARCINOMA, DUCTAL; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DNA PRIMERS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; INTERLEUKIN-4; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884791665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075737     Document Type: Article

References (40)

1. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA, (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-1249.
2. Perez-Mancera PA, Guerra C, Barbacid M, Tuveson DA, (2012) What we have learned about pancreatic cancer from mouse models. Gastroenterology 142: 1079-1092.
3. van Laethem J-L, Verslype C, Iovanna JL, Michl P, Conroy T, et al. (2012) New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol 23: 570-576.
4. Jones S, Zhang X, Parson DW, Lin JC-H, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
5. Morris JP IV, Wang SC, Hebrok M, (2010) KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10: 683-695.
6. McCleary-Wheeler AL, McWilliams R, Fernandez-Zapico ME, (2012) Aberrant signalling pathways in pancreatic cancer: a two compartment view. Mol Carcinogen 51: 25-39.
7. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, et al. (1999) The nuclear factor-κB RelA transcription factor is constitutelively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127.
8. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, et al. (2003) Function of nuclear factor κB in pancreatic cancer metastasis. Clin Cancer Res 9: 346-354.
9. Chandler NM, Canete JJ, Callery MP, (2004) Increased expression of NF-κB subunits in human pancreatic cancer cells. J Surg Res 118: 9-14.
10. Balkwill F, (2009) Tumor necrosis factor and cancer. Nat Rev Cancer 9: 361-371.
11. Wajant H, (2009) The role of TNF in cancer. Results Probl Cell Differ 49: 1-15.
12. Grell M, Douni E, Wajant H, Löhden M, Clauss M, et al. (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83: 793-802.
13. Wajant H, Pfizenmaier K, Scheurich P, (2003) Tumor necrosis factor signalling. Cell Death Differ 10: 45-65.
14. Chen X, Bäumel M, Männel DN, Howard OM, Oppenheim JJ, (2007) Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 179: 154-161.
15. Chen X, Wu X, Zhou Q, Howard OM, Netea MG, et al. (2013) TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T cell phenotype in the inflammatory environment. J Immunol 190: 1076-1084.
16. Chopra M, Riedel SS, Biehl M, Krieger S, von Krosigk V, et al. (2013) Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis 1296-1303.
17. Egberts J-H, Cloosters V, Noack A, Schniewind B, Thon L, et al. (2008) Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 68: 1443-1450.
18. Müller-Hermelink N, Braunmüller H, Pichler B, Wieder T, Mailhammer R, et al. (2008) TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 13: 507-518.
19. Murugesan SR, King CR, Osborn R, Fairweather WR, O'Reilly EM, et al. (2009) Combination of human tumor necrosis factor-alpha (hTNF-α) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene Ther 16: 841-847.
20. Maier HJ, Schmidt-Straßburger U, Huber MA, Wiedemann EM, Beug H, et al. (2010) NF-κB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett 295: 214-228.
21. Furukawa K, Ohashi T, Haruki K, Fujiwara Y, Iida T, et al. (2011) Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice. Cancer Lett 306: 92-98.
22. Röder C, Trauzold A, Kalthoff H, (2011) Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Eur J Cell Biol 90: 450-455.
23. Ariapart P, Bergstedt-Lindqvist S, van Harmelen V, Permert J, Wang F, et al. (2012) Resection of pancreatic cancer normalize the preoperative increase of tumor necrosis factor alpha gene expression. Pancreatology 2: 491-494.
24. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, et al. (1984) Induction and chemotherapeutic response of two transplantable ductal adenocarcinoma of the pancreas in C57BL/6 mice. Cancer Res 44: 717-726.
25. Tepel J, Kruse ML, March C, Fiedler A, Kapischke M, et al. (2004) Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma. Pancreas 28: 1-12.
26. Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, et al. (2005) In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 106: 1113-1122.
27. Orosz P, Echtenacher B, Falk W, Rüschoff J, Weber D, et al. (1993) Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 177: 1391-1398.
28. Hafner M, Orosz P, Krüger A, Männel DN, (1996) TNF promotes metastasis by impairing natural killer cell activity. Int J Cancer 66: 388-392.
29. Mochizuki Y, Nakanishi H, Kodera Y, Ito S, Yamamura Y, et al. (2004) TNF-α promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis 21: 39-47.
30. Chee J, Angstetra E, Mariana L, Graham KL, Carrington EM, et al. (2011) TNF receptor 1 deficiency increases regulatory T cell function in nonobese diabetic mice. J Immunol 187: 1702-1712.
31. Fallon PG, Jolin HE, Smith P, Emson CL, Townsend MJ, et al. (2002) IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity 17: 7-17.
32. Kawakami K, Kawakami M, Husain SR, Puri RK, (2002) Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res 62: 3575-3580.
33. Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M, (2005) Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer 14: 921-928.
34. Li H, Wu K, Tao K, Chen L, Zheng Q, et al. (2012) Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56: 1342-1351.
35. Oomizu S, Arikawa T, Niki T, Kadowaki T, Ueno M, et al. (2012) Cell Surface Galectin-9 Expressing Th Cells Regulate Th17 and Foxp3+ Treg Development by Galectin-9 Secretion. PLoS ONE 7: e48574.
36. Franco L, Doria D, Bertazzoni E, Benini A, Bassi C, (2004) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer. Prostaglandins Other Lipid Mediat 73: 51-58.
37. Takahashi M, Kitahashi T, Ishigamori R, Mutoh M, Komiya M, et al. (2008) Increased expression of inducible nitric oxide synthase (iNOS) in N-nitrosobis(2-oxopropyl)amine-induced hamster pancreatic carcinogenesis and prevention of cancer development by ONO-1714, an iNOS inhibitor. Carcinogenesis 29: 1608-1613.
38. Tepel J, Kruse ML, Kapischke M, Haye S, Sipos B, et al. (2006) Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model. Pancreatology 6: 240-247.
39. Schneider G, Hamacher R, Eser S, Friess H, Schmid RM, et al. (2008) Molecular biology of pancreatic cancer - new aspects and targets. Anticancer Res 28: 1541-1550.
40. Conroy T, Gavoille C, Adenis A, (2011) Metastatic pancreatic cancer: old drugs, new paradigms. Curr Opin Oncol 23: 390-395.